specifying which patients should undergo cardiovascular surveillance following lymphoma treatment
Published 2 months ago • 87 plays • Length 2:13Download video MP4
Download video MP3
Similar videos
-
1:59
assessing if a patient with dlbcl is responding to treatment using pet-ct and novel assays
-
2:22
the need for novel agents to treat patients with mcl who have relapsed after targeted therapy
-
1:48
do all patients require maintenance therapy following allosct?
-
2:45
continuity of care for patients with hematological predispositions to aml
-
1:17
the importance of risk-adapted therapies in hodgkin lymphoma
-
0:45
difference between quality of life & patient-reported outcomes
-
2:42
investigating the treatment preferences of physicians in r/r follicular lymphoma
-
9:25
mgus diagnosis: a step-by-step approach
-
47:22
project management for healthcare
-
1:48
the potential of bispecific antibody-containing combinations in patients with b-cell lymphomas
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
3:06
advice for monitoring patients with different subtypes of t-cell lymphoma
-
7:50
the esc guidelines on cardio-oncology: incorporating the guidelines into clinical practice
-
1:44
the importance of patient-reported outcomes in clinical trials & clinical practice
-
1:27
preventing and monitoring cardiotoxicities associated with treatment for hematologic malignancies
-
1:47
advances in hodgkin lymphoma treatment: moving away from abvd and beacopp
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
1:22
diagnostics and treatment outcomes from primary cbcl
-
1:02
maintenance therapy following treatment for amyloidosis
-
1:45
the role of non-covalent btkis in the era of covalent btkis for b-cell malignancies
-
2:09
heart transplantation in attr amyloidosis